What is the recommended blood glucose target range during treatment of hyperosmolar hyperglycaemic state (HHS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Glucose Target During HHS Treatment

Target blood glucose between 200–250 mg/dL until resolution of hyperosmolar hyperglycemic state, then maintain between 250–300 mg/dL during the first 24 hours to prevent overly rapid osmolality decline. 1

Primary Glucose Targets in HHS

The glucose management strategy in HHS differs fundamentally from DKA because the priority is controlled reduction of osmolality rather than rapid glucose normalization:

  • Keep glucose between 200–250 mg/dL until HHS resolution (defined as osmolality <300 mOsm/kg, corrected hypovolemia, and return to baseline mental status). 1

  • During the first 24 hours, maintain glucose at 250–300 mg/dL to limit osmolality reduction to the safe range of 3–8 mOsm/kg/h and minimize risk of cerebral edema and central pontine myelinolysis. 2, 3

  • Target glucose decline of 50–75 mg/dL per hour once insulin is initiated, but this rate should be achieved primarily through fluid resuscitation rather than aggressive insulin dosing. 2

Critical Timing: When to Add Dextrose

Add 5% or 10% dextrose to IV fluids when plasma glucose reaches 250–300 mg/dL while continuing insulin infusion at a reduced rate of 0.05–0.1 units/kg/h. 2, 4 This prevents overly rapid glucose decline that can precipitate dangerous osmotic shifts. 2

The most common error is adding dextrose too early, which delays correction of hyperosmolarity and prolongs altered mental status. 2

Why HHS Targets Are Higher Than DKA

The 2025 ADA guidelines explicitly differentiate targets: DKA requires glucose 150–200 mg/dL until resolution, whereas HHS requires 200–250 mg/dL. 1 This reflects three key differences:

  • HHS patients have more severe hyperosmolarity (≥320 mOsm/kg vs. variable in DKA), making rapid osmolality correction dangerous. 2

  • Neurological complications are more common in HHS, with mortality up to 15% compared to <1% in DKA. 2, 3

  • Fluid replacement alone causes significant glucose decline in HHS, so insulin should be withheld until glucose stops falling with IV fluids alone (unless ketonemia is present). 5, 3

Insulin Management Specific to HHS

  • Delay insulin initiation until blood glucose is no longer falling with IV fluid administration alone, unless ketonemia (≥3.0 mmol/L) is present. 2, 5, 3

  • Start with IV bolus of 0.1–0.15 units/kg regular insulin, followed by continuous infusion at 0.1 units/kg/h. 2, 6

  • Reduce insulin infusion to 0.05–0.1 units/kg/h once dextrose is added at glucose 250–300 mg/dL. 2, 4

Monitoring Requirements

  • Check blood glucose every 2–4 hours along with serum electrolytes, osmolality, and venous pH until stable. 1, 2

  • Calculate effective osmolality as 2[Na (mEq/L)] + glucose (mg/dL)/18 to guide therapy; aim for reduction of 3–8 mOsm/kg/h. 2, 3

  • Correct serum sodium for hyperglycemia by adding 1.6 mEq/L for each 100 mg/dL glucose above 100 mg/dL to assess true sodium status. 2

Resolution Criteria

HHS is considered resolved when all of the following are met: 3

  • Osmolality <300 mOsm/kg
  • Hypovolemia corrected (urine output ≥0.5 mL/kg/h)
  • Cognitive status returned to pre-morbid baseline
  • Blood glucose <15 mmol/L (270 mg/dL)

Common Pitfalls to Avoid

  • Never target euglycemia during acute HHS treatment—this causes dangerous osmotic shifts and increases mortality. 2, 3

  • Do not start insulin before adequate fluid resuscitation unless significant ketonemia is present; early insulin use may be detrimental. 5, 3

  • Avoid rapid glucose decline below 250 mg/dL in the first 12–24 hours, as this correlates with increased risk of cerebral edema and central pontine myelinolysis. 2, 3

  • Monitor for rebound hyperglycemia when transitioning from IV to subcutaneous insulin; administer basal insulin 2–4 hours before stopping the IV infusion. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hyperosmolar Hyperglycemic State Diagnostic Criteria and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Hyperglycemic Hyperosmolar State in Remission

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Management of hyperosmolar hyperglycaemic state in adults with diabetes.

Diabetic medicine : a journal of the British Diabetic Association, 2015

Research

Hyperosmolar hyperglycemic state.

American family physician, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.